cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes Novo Nordisk's Cagrilintide shows promising

Escape the algorithm

The FASEB Journal, 21, 18441856

How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential

Bad storage leads to bad science

At your initial consultation, well help you determine the ideal schedule for your specific situation and goals

During propagation, lipid radicals react with molecular oxygen to form lipid peroxyl radicals (LOO), which subsequently abstract hydrogen atoms from adjacent phospholipids, thereby generating new lipid radicals and lipid hydroperoxides (LOOH)